Neuropsychological prediction of dementia in Parkinson’s disease

Florence Mahieux, Gilles Fénelon, Antoine Flahault, Marie-José Manifacier, Denyse Michelet, François Boller

Abstract

Objective—To identify neuropsychological characteristics predictive of later dementia in Parkinson’s disease.

Methods—A comprehensive neuropsychological test battery was administered to a cohort of 89 initially non-demented patients with Parkinson’s disease consecutively enrolled at a specialised Parkinson’s disease clinic. They were reassessed after a mean of 3.5 years for the diagnosis of dementia. The Cox proportional hazards model was used to identify baseline characteristics predictive of dementia.

Results—Only four of the baseline clinical characteristics of Parkinson’s disease and neuropsychological variables remained independently linked to subsequent development of dementia: the age of onset of Parkinson’s disease (>60 years; relative risk (RR) 4.1, 95% confidence interval (95% CI) 1.8–24.0, p<0.03), the picture completion subtest of the Wechsler adult intelligence scale (score<10; RR 4.9, 95% CI 1.0–24.1, p<0.02), the interference section of the Stroop test (score<21; RR 3.8, p=0.08), and a verbal fluency task (score<9; RR 2.7, 95% CI 0.8–9.1, p=0.09).

Depressive symptoms and the severity of motor impairment were not predictive of dementia.

Conclusion—These features are different from the neuropsychological characteristics predictive of Alzheimer’s dementia in healthy elderly people (mainly memory and language performance). They are in keeping with the well known specificity of the impairments in Parkinson’s disease for visuospatial abilities and difficulties in inhibiting irrelevant stimuli. It is postulated that the composite nature of the picture completion subtest, involving several cognitive abilities impaired in Parkinson’s disease, explains its sensitivity.

Keywords: Parkinson’s disease; dementia; visuospatial; attention; frontal

Several cross sectional neuropsychological investigations of Parkinson’s disease have indicated that, relative to age matched normal controls, non-demented patients with Parkinson’s disease are impaired in several cognitive tasks. Precise identification of the impaired processes and their explanations in terms of cognitive models have generated a vigorous debate.1–3 However, these mild cognitive dysfunctions do not progress to full dementia in all patients with Parkinson’s disease4; and the precise frequency5–18 and aetiology19–23 of dementia are controversial. Patients with Parkinson’s disease with dementia respond poorly to treatment, often develop adverse drug reactions, and have a poorer vital prognosis than patients with Parkinson’s disease without dementia.2 Early detection of preclinical signs predictive of late dementia would have considerable clinical, therapeutic, and public health value. Few studies have investigated risk factors for dementia in Parkinson’s disease.4 19–20 Results from these studies indicate that older age,21 25 older age at onset,21 25 more severe disease,16–20 longer duration of Parkinson’s disease,4 poorer initial performance on the verbal scale of the Wechsler adult intelligence scale (WAIS),4 depressive symptoms,15 24–28 psychotic adverse responses to levodopa,24–28 cardiovascular abnormalities,27 and a family history of dementia26 are associated with later onset of dementia. Although many of these characteristics are important and easy to record, neuropsychological studies could provide more accurate clues as to why frequent early subtle cognitive disorders do not always lead to later dementia. Jacobs et al29 reported that, in addition to age, disease severity, and depression, baseline performance in two verbal fluency tasks was significantly and independently associated with incident dementia. We previously performed a study30 aiming to validate a new bedside test, the mini mental Parkinson test (MMP) which allowed us to record a cohort of patients. The use in this study of a much larger neuropsychological test battery than that used by Jacobs et al29 and the follow up period, provided us with an opportunity to study their outcome with regard to dementia.

Methods

SUBJECTS

The patient cohort was initially selected for the MMP study. It involved 89 patients enrolled between 1990 and 1993 for the validation of two successive versions of a bedside test30 aimed at rapidly identifying specific Parkinson’s neuropsychological disorders. Patients were enrolled consecutively from a specialised Parkinson’s disease clinic of a hospital neurological department. All the patients were initially examined at the neurological unit of Tenon hospital, and were considered to have idiopathic Parkinson’s disease. All
were dementia free according to DSM III-R criteria, and were parkinsonian outpatients residing in the community. They were ineligible if they had life threatening medical conditions, other neurological conditions, or severe sensory impairment that might interfere with the tests. As major depression is a known confounding factor for neuropsychological disorders, patients meeting DSM III-R criteria for current major depression were excluded, although patients treated with antidepressant drugs were eligible (15 cases). Depressive symptoms were assessed in all cases.

Subsequently, we decided to determine the incidence of dementia in this population. Charts were reviewed after October 1995. We required either (1) a diagnosis of dementia recorded by a neurologist according to DSM-III-R criteria or (2) recorded evidence of all signs and symptoms of dementia (eight cases). Follow up information was available for 86 of the 89 patients. One patient was lost to follow up, and dementia could not be assessed in two patients who died. For 43 patients data were recorded at Tenon hospital, and seven additional patients were recontacted directly. Dementia was diagnosed on the basis of a questionnaire filled in by neurologists from other hospitals in 22 cases. This questionnaire included a detailed description of all DSM-III-R criteria with special emphasis on abstract thinking, impaired judgment, and ability to manipulate acquired knowledge. In 14 cases the same questionnaire was filled in by a general practitioner and confirmed by a telephone interview with a neurologist. Finally, five patients were excluded from further analyses because, during follow up, the initial diagnosis of Parkinson’s disease was found to be incorrect according to the criteria of the United Kingdom Parkinson’s Disease Society Brain Bank (one met clinical criteria for dementia with Lewy bodies, one for progressive supranuclear palsy, one for progressive supranuclear palsy, one for progressive supranuclear palsy). Disease manifestations at the initial diagnosis were scored according to the unified Parkinson’s disease rating scale (UPDRS) and the Hoehn and Yahr scale. The Center for Epidemiologic Studies depression (CES-D) and Zung anxiety self rating scales (French translation) were filled in by the patients. Previous adverse effects of therapy (confusion or psychosis) were recorded and combined for this analysis.

STATISTICAL METHODS
We used a stepwise Cox proportional hazards model for censored data. The time from baseline to the visit at which dementia was diagnosed was used as the timing variable for Cox analyses. For patients who remained free of dementia, we used the time from baseline to the last available follow up visit. All the continuous variables at baseline (including neuropsychological performance and clinical characteristics) were dichotomised. The cut off values were the median of each index. To reduce the large number of variables, they were selected in a two step process. Firstly, each variable was compared between the patients who became demented and those who remained free of dementia in univariate analysis (by using a log rank test). All clinical and neuropsychological variables were included in this analysis, together with the MMSE orientation item. Those variables with two sided significance (p<0.05) were then submitted to a Cox proportional hazards multivariate model. On the basis of previous studies the UPDRS items “facial mask”, “bradykinesia of hands”, and “speech”, and the UPDRS total motor examination score, age at onset, and CES-D score were also included as covariates, whatever their level of significance in the univariate analysis. The p value limit for entering the covariates in the model was set at 0.10. Hazard ratios were estimated with 95% confidence intervals (95% CIs).

SAMPLE SIZE
As the variables submitted to the multivariate model were dichotomised with the median as cut off, the size of the exposed group was equal to that of the unexposed group for each covariate of interest. At a significance of 5% and
with a power of 80%, 10 events must be expected in the unexposed group to detect a relative risk >2.5 (three events for a relative risk (RR) ≥ 5).

BMDP statistical software was used for all the analyses.

**Results**

Of the 89 patients originally examined, 81 were included in the analyses. Their mean (SD) age was 66.9 (10.0) years, and there were 35 women and 46 men. Their mean number of years of education was 11.3 (SD 4.4). The mean duration of Parkinson’s disease was 8.3 (SD 6.5) years. The mean UPDRS motor examination score was 17.9 (SD 14.4). The mean duration of follow up was 3.5 (SD 1.5) years.

A total of 19 patients became demented during the follow up period, resulting in an incidence rate of 67.2/1000 person-years in this sample (Poisson 95% CI 40.3–105.1).

Table 1 shows the baseline characteristics of the patients who did and who did not become demented. Patients who became demented were older, had a higher motor examination score (UPRS III), and were more likely to have psychotic adverse events. They had a significantly lower score in Folstein’s MMSE. The two groups did not differ significantly in terms of education, sex, history of smoking, Hoehn and Yahr stage, severity of facial mask and bradykinesia of hands, disease duration, or the anxiety and depression scores.

Nine of the neuropsychological variables (table 2) did not differ significantly between the two groups and were not retained for multivariate analysis (vocabulary, similarities, arithmetic, span, associate memory, Benton line orientation test, WCST errors and perseverative errors, and MMSE orientation item).

When the remaining variables were submitted to the Cox regression model along with the covariates (age at onset, education, CES-D, side of onset, mask face, and psychotic adverse events), four variables remained independent predictors (table 3): age at onset (p = 0.02), the picture completion subtest of the WAIS-R (p = 0.03), the coloured word part of the Stroop test (p = 0.08) and verbal fluency (letter M) (p = 0.09), although the last two were only close to significance. Table 2 presents the RR estimates. The median age at onset of Parkinson’s disease was 60 years; patients with Parkinson’s disease older than 60 years had a 4.1-fold higher risk of developing dementia. The median value for the WAIS-R picture completion subtest was 9.5; an observed raw score < 10 was associated with an RR of 4.9. The median Stroop score was 20; patients who named less than 21 colours in the third part of the Stroop test had a 3.8-fold higher risk of developing dementia. The median letter fluency score was 8.5; patients who had a 2.7-fold higher risk of developing dementia within three and half years if they found fewer than nine words beginning with the letter M in one minute.

To assess the potential for misdiagnosis we performed the same multivariate analysis after (a) exclusion of the 14 patients in whom dementia was diagnosed by general practitioners, and (b) exclusion of the three patients with MMSE < 23. The results were only slightly modified. The WAIS-R completion subtest and age at onset remained significant and independent predictors of dementia in the two subanalyses. Verbal fluency remained as a trend (p = 0.09) but the Stroop test did not in the first subanalysis; in the second the Stroop interference subtest remained as a trend (p = 0.07) but verbal fluency did not.

**Discussion**

In a sample of 81 initially non-demented patients with Parkinson’s disease, we found that four baseline clinical characteristics and...
Neuropsychological variables remained independently linked to subsequent development of dementia: the age of onset of Parkinson’s disease (>60 years), the picture completion subtest of the WAIS-R (raw score < 10), the C part of the Stroop test (number of colours named = 21), and a verbal fluency task (nine words). Unlike other authors, we found no predictive value of depressive symptoms or UPDRS motor scores. The predictive value of older age at onset has long been known. The predictive value of poorer performance in verbal fluency tasks was recently described by Jacobs et al. The use of a comprehensive neuropsychological test battery to assess a range of cognitive domains, which was not explored by Jacobs et al., disclosed the higher predictive value of the picture completion subtest of the WAIS-R.

The WAIS-R picture completion subtest consists of finding, in a card series, a missing detail in a familiar picture (door handle, eyebrow in a face, dog’s tracks, shadow in a landscape). The task is time limited and is known to require several cognitive abilities, such as sustained attention (for close inspection of material), shape or situation analysis (relevant to visuoperceptual abilities), and developing new strategies across different cards. All of these abilities are often impaired in Parkinson’s disease. The impairment of patients with Parkinson’s disease in the WAIS performance subset is well known. These tests have fallen into disuse for research purposes, in favour of more comprehensive tasks attempting to examine more specific neuropsychological processes in Parkinson’s disease. The fact that this test was the only one to remain a highly significantly independent predictor of later dementia could be explained by its composite nature, which may be broader than that of the other tasks in this study, rather than by the identification of a specific cognitive ability impaired early in the dementia process. This composite nature could render it especially sensitive to very mild deteriorations.

We agree with Jacobs et al., who interpreted the predictive value of impaired verbal fluency as an impairment of planning and initiating a systematic search in semantic memory rather than a primary impairment of language. They proposed to relate the discrepant findings of previous cross-sectional studies on verbal fluency to differences in task instructions. Unlike the previous study, we did not give the patients cues such as superordinate categories. This could explain why the category fluency task did not remain an independent predictor of dementia in the current study. It could also be that alternating category and letter fluency tasks require the ability to shift between mental sets, an ability that was explored with more specific tasks in the present study.

The Stroop test consists of three sections. In the first, patients are required to read aloud, as fast as possible, words (colour names) written in columns. The second section consists of a series of columns printed in coloured ink, the task being to name the ink colours as fast as possible. The third (interference) section consists of words (always names of colours) printed in columns, the ink colours differing from the written word (for instance word “green” printed in blue ink). The task is to name as fast as possible the ink colours, ignoring the written word. All Stroop sections reflect slowing down of information processing. The third part specifically concerns proactive interference and the ability to ignore irrelevant stimuli. Some authors have argued that “ignoring irrelevant stimulus” dimension could be a highly specific attentional dysfunction in parkinsonian patients. As pointed out by Downes et al., “the idea that inhibitory attentional processes are less efficient in Parkinson’s disease is consistent with Hassler’s early contention that the basal ganglia are critical for the suppression of extraneous information”.

In a recent study of a subgroup of parkinsonian patients showing pronounced frontal type cognitive impairment, low scores in verbal fluency and Stroop tests correlated with a severe decrease in the later component of auditory evoked potential Nd2, considered to reflect regulating frontal processes during selective attention.

The lack of association between the occurrence of dementia and the UPDRS motor examination score in our sample could be explained by a much milder impairment of our patients relative to those in the study of Jacobs et al., although the duration of Parkinson’s disease seems to be similar in the two samples. This finding has to be confirmed in larger studies involving a wide range of patients. Fatiguability, motor impairment, slowing down, and dyskinesia hinder in depth evaluation, especially of the most strongly impaired patients. The possibility that these physical limitations mask early deterioration cannot be ruled out.

The lack of association between the occurrence of dementia and depressive symptoms in our sample could be due to a recruitment bias, as we excluded patients with major depression from the MMP validation study. Recent population studies showed that the prevalence of major depression, based on DSM-IIIR criteria, is lower than previously estimated (< 8%), although the prevalence of depressive symptoms is high. However, 36 patients in our study scored above the cut off for depression on the self administered CES depression scale (although this kind of scale must be interpreted cautiously in Parkinson’s disease), a prevalence very close to that found by Tanberg et al. Depression is often considered as an important factor associated with cognitive impairment in Parkinson’s disease. For others, the effect of mood on the performance of cognitive tests is, at best, partial. In a recent study Tröster et al. found that depression exacerbated some memory and language impairments associated with Parkinson’s disease—namely, verbal fluency (category as well as letter retrieval), the Boston naming test and logical memory. A higher prevalence of depressive symptoms in the sample of Jacobs et al. could, at least in part, explain the discrepancies in the impact of...
depression and the relative importance of fluency tasks in the two studies.

The demented group in our study had a significantly lower MMSE at the first assessment, giving evidence of clear cognitive dysfunction. The dementia might thus already have begun in this group. This calls for two comments. Firstly, the MMSE is a bedside test designed to screen for Alzheimer type dementia, but its dependence on cultural level is well known and hinders the use of a rigid cut off score. For the diagnosis of dementia in other cognitive disorders, its reliability is far from demonstrated. However, its worldwide use makes it convenient for grossly evaluating and comparing the global level of cognitive function in clinical samples. Secondly, patients with Parkinson’s disease are not comparable with healthy subjects. Cognitive disorders present in nearly all patients with Parkinson’s disease are widely described, and Growdon and Corkin emphasised that clinically non-demented patients with Parkinson’s disease may score outside the normal range on MMSE. The sample studied here was not composed of de novo patients (although 30 of them had less than a five year disease history at the first assessment), but was a representative sample of all patients with Parkinson’s disease seen at a neurological consultation. The search for neuropsychological predictors of dementia assumes that the process responsible for dementia begins long before its full clinical expression and that mild neuropsychological disorders due to this process can be identified.

The use of DSM-III-R criteria for the diagnosis of dementia in Parkinson’s disease has been criticised because of the clinical differences between Alzheimer’s disease dementia and Parkinson’s disease dementia. For instance, the primacy of memory loss seems typical of Alzheimer’s disease but not Parkinson’s disease, whereas disturbances of attention, motivation, accessing and manipulating knowledge, and psychomotor slowing, are typical of Parkinson’s disease dementia. These differences led to the concept of subcortical dementia. However, the validity of this concept is still controversial. Consensus discussions on clinical criteria for the diagnosis of dementia in Parkinson’s disease would be desirable, although such criteria will be difficult to establish because of the probable heterogeneity of dementia in Parkinson’s disease. In addition, the social and clinical decline related to cognitive disorders is difficult to identify, as the motor deficit limits activities and leads to dependency. Finally, the continuous distribution of cognitive disorders in Parkinson’s disease makes it difficult to identify the moment at which they are sufficient to diagnose dementia. No operational criteria specifically designed for Parkinson’s disease dementia are available. Despite the above limitations, DSM criteria remain the best choice as they vastly improve the accuracy and consistency of dementia diagnoses. Finally, the fact that neuropsychological predictors of dementia in our Parkinson’s disease cohort were not the same as those described as predictors of Alzheimer’s disease (see next paragraph) is a good argument that DSM-III-R criteria did not only select Alzheimer’s disease.

The neuropsychological pattern characterising the preclinical stages of dementia in Parkinson’s disease differed from that reported in the two papers describing the neuropsychological characteristics of preclinical dementia of the Alzheimer type in healthy elderly subjects. Masur et al found that delayed recall in the Buschke selective reminding test, recall in the Fuld object memory evaluation, the WAIS digit symbol subtest, and a verbal fluency score at the baseline assessment identified a subgroup of healthy subjects with an 85% probability of developing dementia during the follow up period. Similarly, Jacobs et al found that scores in the Boston naming test, immediate recall on the selective reminding test, and the WAIS-R similarities subtest were significantly and independently associated with a later diagnosis of Alzheimer’s disease. The problem of preclinical detection of dementia is substantially different in Parkinson’s disease and Alzheimer’s disease. In the second, the key is to identify healthy elderly subjects who have subtle cognitive changes well before the overt clinical signs of dementia occur. In Parkinson’s disease the problem is to select, among a broad range of neuropsychological abnormalities, those predictive of later dementia. The different cognitive profiles for preclinical dementia in Parkinson’s disease and Alzheimer’s disease are in keeping with the well known differences between demented patients with Parkinson’s disease and those with Alzheimer’s disease: the core symptoms of preclinical Alzheimer’s disease involve essentially memory and language tasks, whereas the core symptoms of preclinical dementia in Parkinson’s disease involve executive functions rather than memory. This may reflect different pathological substrates for the dementia syndromes associated with these two diseases. As in many other neurological studies of dementia, our findings are limited by the impossibility of obtaining an aetiological diagnosis. Although 23 of the patients included in our analysis died, none underwent postmortem examination. Thus we are unable to attribute the dementia to Alzheimer’s disease, diffuse Lewy bodies, or another cause, all of which could at least partially modify the neuropsychological pattern forerunning each form of dementia.

Our finding that impaired picture completion and word retrieval are predictive of subsequent dementia confirms and extends the results of Jacobs et al. Further studies are needed to confirm these data on different samples. However, these two simple tasks could be included routinely in the first assessment of patients with Parkinson’s disease and be used as copredictors of a high risk of psychotic adverse events to therapy.

This study was supported in part by a grant from Produits Roche France (1990 Roche Prize). We are grateful to David Young for patient revision of the English.
